Literature DB >> 9829010

Health economics and cost implications of anxiety and other mental disorders in the United States.

D P Rice1, L S Miller.   

Abstract

BACKGROUND: Mental disorders impose a multi-billion dollar burden on the economy each year; translating the burden into economic terms is important to facilitate formulating policies about the use of resources.
METHODS: For direct costs, data were obtained from national household interview and provider surveys; for morbidity costs, a timing model was used that measures the lifetime effect on current income of individuals with mental disorders, taking into account the timing of onset and the duration of these disorders, based on regression analysis of Epidemiologic Catchment Area study data.
RESULTS: The total economic costs of mental disorders amounted to US$147.8 billion in 1990. Anxiety disorders are the most costly, amounting to $46.6 billion, or 31.5% of the total; schizophrenic disorders accounted for $32.5 billion, affective disorders for $30.4 billion, and other mental disorders for $38.4 billion.
CONCLUSIONS: Mental illnesses, especially anxiety disorders, are costly to society. Although anxiety disorders have a higher prevalence than affective disorders and schizophrenia, use of medical care services is lowest for anxiety disorders. Anxiety disorders appear to be under-recognised and untreated even though treatment interventions have been shown to be effective and can be delivered in a cost-efficient manner.

Entities:  

Mesh:

Year:  1998        PMID: 9829010

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  56 in total

1.  What the millennium bug tells us about ourselves. Y2K anxiety is provoked by unlimited ambiguity with a concrete deadline.

Authors:  J Anderson
Journal:  BMJ       Date:  1999-08-21

Review 2.  Mind matters: the importance of mental disorders in public health's 21st century mission.

Authors:  R Neugebauer
Journal:  Am J Public Health       Date:  1999-09       Impact factor: 9.308

3.  Estimating the prevalence of mental and somatic disorders in the community: aims and methods of the German National Health Interview and Examination Survey.

Authors:  Frank Jacobi; Hans-Ulrich Wittchen; Christoph Hölting; Sieghard Sommer; Roselind Lieb; Michael Höfler; Hildegard Pfister
Journal:  Int J Methods Psychiatr Res       Date:  2002       Impact factor: 4.035

4.  Associations of serious mental illness with earnings: results from the WHO World Mental Health surveys.

Authors:  Daphna Levinson; Matthew D Lakoma; Maria Petukhova; Michael Schoenbaum; Alan M Zaslavsky; Matthias Angermeyer; Guilherme Borges; Ronny Bruffaerts; Giovanni de Girolamo; Ron de Graaf; Oye Gureje; Josep Maria Haro; Chiyi Hu; Aimee N Karam; Norito Kawakami; Sing Lee; Jean-Pierre Lepine; Mark Oakley Browne; Michail Okoliyski; José Posada-Villa; Rajesh Sagar; Maria Carmen Viana; David R Williams; Ronald C Kessler
Journal:  Br J Psychiatry       Date:  2010-08       Impact factor: 9.319

Review 5.  Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.

Authors:  Alan Haycox
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 6.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

7.  Norepinephrine transporter inhibitors and their therapeutic potential.

Authors:  Jia Zhou
Journal:  Drugs Future       Date:  2004-12       Impact factor: 0.148

Review 8.  Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective.

Authors:  Mauro Percudani; Corrado Barbui; Michele Tansella
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  Mental health treatment received by primary care patients with posttraumatic stress disorder.

Authors:  Benjamin F Rodriguez; Risa B Weisberg; Maria E Pagano; Jason T Machan; Larry Culpepper; Martin B Keller
Journal:  J Clin Psychiatry       Date:  2003-10       Impact factor: 4.384

10.  Overview and emerging trends.

Authors:  Sandeep Grover; Ajit Avasthi; Subho Chakrabarti; Paramanand Kulhara
Journal:  Indian J Psychiatry       Date:  2005-10       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.